" class="no-js "lang="en-US"> Mnemo Therapeutics - Medtech Alert
Saturday, September 30, 2023
Mnemo Therapeutics | Pharmtech Focus

Mnemo Therapeutics

About Mnemo Therapeutics

Mnemo Therapeutics

Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.

Related Story

Mnemo Therapeutics Names Robert LaCaze as Chief Executive Officer

February 23 2022

Mnemo Therapeutics, a biotechnology company developing next-generation T cell therapies, today announced the appointment of Robert […]

Research Demonstrates Novel HIT Receptor Enhances T Cell Antigen Sensitivity and Elicits Superior Tumor Control

January 24 2022

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance […]

Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform

June 18 2021

Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, […]